Your session is about to expire
← Back to Search
Terameprocol for Brain Tumor
Study Summary
This trial is testing the side effects and best dosage of a drug called terameprocol in treating patients with high-grade glioma that has returned.
- Brain Tumor
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You cannot participate if you are already taking any other experimental medications.You have received nitrosourea chemotherapy within the past 6 weeks.You have received a type of chemotherapy other than nitrosourea within the past 3 weeks.The surgeon should be able to remove a certain amount of tumor during surgery without causing harm to the brain.
- Group 1: Treatment (terameprocol)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many facilities are implementing this experiment?
"UAB Comprehensive Cancer Center in Birmingham, Alabama; Abrams Cancer Center of the University of Pennsylvania in Philadelphia, Pennsylvania; and Josephine Ford Cancer Center at Henry Ford Hospital in Detroit, Michigan are just some of the medical centres actively recruiting for this clinical trial. An additional 8 sites have also been identified as potential enrolment locations."
Have any other investigations explored the use of Terameprocol?
"At present, there is one ongoing clinical trial researching the effects of Terameprocol. It has yet to reach Phase 3 and is currently running out of 10 different medical centres, with a notable presence in New york City."
To what extent are individuals partaking in this experiment?
"This clinical trial is not currently accepting any more candidates. Initially posted on May 3rd 2018, the study was last modified on August 5th 20202. Although this research is closed to new patients, there are 356 trials recruiting glioma participants and one investigation looking for Terameprocol volunteers presently in progress."
Has Terameprocol been accepted by the FDA for use?
"Given its status as a Phase 1 trial, which involves limited data about safety and efficacy, our team at Power assessed Terameprocol's safety with an estimated score of 1."
Is this endeavor the inaugural attempt at a similar experiment?
"Since its initial clinical trial in 2018, sponsored by Erimos Pharmaceuticals and involving 20 patients, Terameprocol has gone through the Phase 1 drug approval stage. Currently, there is one ongoing research led by Erimos Pharmaceuticals that involves this medication."
Are there any open slots available for this medical research project?
"This trial is temporarily closed for recruitment, with the original posting date being May 3rd 2018 and its most recent update on August 5th 2022. However, there are presently 356 clinical trials enrolling patients suffering from glioma and one active medical study recruiting participants to test Terameprocol."
Share this study with friends
Copy Link
Messenger